Speaker illustration

Professor Florian Kronenberg

Medical University of Innsbruck, Innsbruck (Austria)

Florian Kronenberg received his MD from the University of Innsbruck, Austria. After his training in Medical Genetics in Gerd Utermann's lab, he worked with Roger R. Williams and Steve Hunt at the University of Utah, USA. Later, he headed the Research Unit "Genetic Epidemiology" at the Institute of Epidemiology, Helmholtz Center Munich. In 2004, he became full professor and head of the Institute of Genetic Epidemiology at the Medical University of Innsbruck. Research interests: genetic and clinical epidemiological studies on lipoprotein(a). He is Co-Editor of "Atherosclerosis" and served as workgroup member on several guideline and consensus initiatives (K/DOQI, KDIGO and EAS). He chaired the most recent EAS Consensus Statement on Lp(a) (together with S. Mora and E. Stroes). He has published more than 500 papers including 400 original papers and roughly 100 review articles, editorials and book chapters. H-index: 92 (Publons) and 108 (Google Scholars) with roughly 48,000 citations.

Strategies to inhibit Lp(a)

Event: ESC Congress 2024

Topic: Lipid-Lowering Agents

Session: Targeting lipids above and beyond statins: key new players

Thumbnail

Lp(a) testing is simple

Event: ESC Congress 2024

Topic: Lipids

Session: Lp(a): not so "little" anymore the role of Lp(a) in cardiovascular risk assessment and clinical practice

Thumbnail

Why measure Lp(a) and what to do about it?

Event: ESC Congress 2023

Topic: Risk Factors and Prevention

Session: Targeting the spectrum of atherogenic lipoproteins: what to do and how to do it

Thumbnail

Lp(a) in clinical practice-risk estimation and how to reduce its associated risk.

Event: ESC Congress 2022

Topic: Lipids

Session: EAS Consensus on Lp(a) 2022 - what to measure, in whom to measure, how to interpret and what to do

Thumbnail

Discussion.

Event: ESC Congress 2022

Topic: Lipid-Lowering Agents

Session: Lp(a): from causality to therapy

Thumbnail

Lp(a) as independent causal risk factor: why should we focus on testing?

Event: ESC Congress 2022

Topic: Lipid-Lowering Agents

Session: Lp(a): from causality to therapy

Thumbnail

Understanding the increased cardiovascular risk of high Lp(a) levels.

Event: ESC Congress 2021 - The Digital Experience

Topic: Risk Factors and Prevention

Session: Lp(a): From CV risk marker to therapeutic target

Thumbnail